Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
US11131676B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 24, 2017 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Sep 13, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.